• 제목/요약/키워드: Drug repositioning

검색결과 26건 처리시간 0.025초

Repositioned Drugs for Inflammatory Diseases such as Sepsis, Asthma, and Atopic Dermatitis

  • Prakash, Annamneedi Venkata;Park, Jun Woo;Seong, Ju-Won;Kang, Tae Jin
    • Biomolecules & Therapeutics
    • /
    • 제28권3호
    • /
    • pp.222-229
    • /
    • 2020
  • The process of drug discovery and drug development consumes billions of dollars to bring a new drug to the market. Drug development is time consuming and sometimes, the failure rates are high. Thus, the pharmaceutical industry is looking for a better option for new drug discovery. Drug repositioning is a good alternative technology that has demonstrated many advantages over de novo drug development, the most important one being shorter drug development timelines. In the last two decades, drug repositioning has made tremendous impact on drug development technologies. In this review, we focus on the recent advances in drug repositioning technologies and discuss the repositioned drugs used for inflammatory diseases such as sepsis, asthma, and atopic dermatitis.

머신러닝 기반의 신약 재창출 관련 연구 동향 분석 (Analysis of Research Trends Related to drug Repositioning Based on Machine Learning)

  • 유소연;임규건
    • 경영정보학연구
    • /
    • 제24권1호
    • /
    • pp.21-37
    • /
    • 2022
  • 신약을 개발하는 한 가지 방법의 하나인 신약 재창출(Drug Repositioning)은 이미 사람들에게 사용할 수 있도록 승인된 약물들이 다른 용도로 사용되도록 하여 새로운 적응증을 발견하는 유용한 방법이다. 최근에는 머신러닝 기술의 발달로 방대한 생물학적 정보를 분석하여 신약 개발에 활용하는 경우가 증가하고 있다. 신약 재창출에 머신러닝 기술을 활용하면 효과적인 치료법을 신속하게 찾아내는 데 도움을 줄 것이다. 현재 심각한 급성 호흡기 증후군인 코로나바이러스(COVID-19)에 의한 신종 질병으로 전 세계가 힘든 시간을 보내고 있다. 이미 임상적으로 승인된 약물의 용도를 변경하는 신약 재창출은 COVID-19 환자를 치료하기 위한 치료제의 대안이 될 수 있다. 본 연구는 머신러닝 기법을 활용하여 신약 재창출 분야에 대한 연구 동향을 살펴보고자 한다. Pub Med에서 웹 스크래핑 기법을 사용하여 'Drug Repositioning'이라는 키워드로 총 4,821건의 논문을 수집하였다. 데이터 전처리 후, 4,419건의 논문을 대상으로 빈도분석, LDA 기반 토픽모델링, Random Forest 분류 분석 및 예측 성능평가를 수행하였다. Word2vec 모델을 기반으로 연관어를 분석하였고, PCA 차원 축소 후 K-Means 군집화하여 레이블을 생성한 후, t-SNE 알고리즘을 이용하여 논문이 형성하고 있는 그룹을 시각화하고, LDA 결과에 계층적 군집화를 적용하여 히트맵으로 시각화하였다. 본 연구는 신약 재창출과 관련된 연구 주제가 무엇인지를 파악하고, 머신러닝 알고리즘을 사용하여 대량의 문헌에서 의미 있는 주제를 도출하고 시각화하는 방법을 제시하였다. 향후 신약 재창출 분야의 연구나 개발 전략을 수립하기 위한 기초자료로 활용되는 데 도움을 줄 것이라고 기대한다.

분산 슈퍼컴퓨팅 기술에 기반한 신약재창출 시뮬레이션 사례 연구 (A Case Study of Drug Repositioning Simulation based on Distributed Supercomputing Technology)

  • 김직수;노승우;이민호;김서영;김상완;황순욱
    • 정보과학회 논문지
    • /
    • 제42권1호
    • /
    • pp.15-22
    • /
    • 2015
  • 본 논문에서는 대규모의 계산 작업을 고성능으로 처리해야 하는 신약재창출 시뮬레이션 분야에 분산 슈퍼컴퓨팅 기술을 적용한 사례에 대해 논의하고자 한다. 신약재창출이란 기존에 알려진 약물의 새로운 적응증을 규명하는 것을 의미하며, 이러한 신약재창출은 비교적 짧은 수행시간을 갖는 대규모의 도킹(docking) 연산들을 고성능으로 처리해야한다는 점에서 Many-Task Computing (MTC) 성격을 지니고 있다. 이러한 MTC 응용들의 대표 사례로서 신약재창출 시뮬레이션을 분산 슈퍼컴퓨팅 환경 기반의 HTCaaS 시스템에 적용하였으며, 이를 통해 효율적인 작업 배포, 동적인 자원 할당 및 로드 밸런싱, 안정성 및 다양한 자원들의 효율적인 통합 등이 이러한 과학 응용들을 지원하는 데 있어 필수적인 기능임을 확인할 수 있었다.

Target Prediction Based On PPI Network

  • Lee, Taekeon;Hwang, Youhyeon;Oh, Min;Yoon, Youngmi
    • 한국컴퓨터정보학회논문지
    • /
    • 제21권3호
    • /
    • pp.65-71
    • /
    • 2016
  • To reduce the expenses for development a novel drug, systems biology has been studied actively. Target prediction, a part of systems biology, contributes to finding a new purpose for FDA(Food and Drug Administration) approved drugs and development novel drugs. In this paper, we propose a classification model for predicting novel target genes based on relation between target genes and disease related genes. After collecting known target genes from TTD(Therapeutic Target Database) and disease related genes from OMIM(Online Mendelian Inheritance in Man), we analyzed the effect of target genes on disease related genes based on PPI(Protein-Protein Interactions) network. We focused on the distinguishing characteristics between known target genes and random target genes, and used the characteristics as features for building a classifier. Because our model is constructed using information about only a disease and its known targets, the model can be applied to unusual diseases without similar drugs and diseases, while existing models for finding new drug-disease associations are based on drug-drug similarity and disease-disease similarity. We validated accuracy of the model using LOOCV of ten times and the AUCs were 0.74 on Alzheimer's disease and 0.71 on Breast cancer.

An In Silico Drug Repositioning Strategy to Identify Specific STAT-3 Inhibitors for Breast Cancer

  • Sruthy Sathish
    • 통합자연과학논문집
    • /
    • 제16권4호
    • /
    • pp.123-131
    • /
    • 2023
  • Breast cancer continues to pose a substantial worldwide health challenge, thereby requiring the development of innovative strategies to discover new therapeutic interventions. Signal Transducer and Activator of Transcription 3 (STAT-3) has been identified as a significant factor in the development of several types of cancer, including breast cancer. This is primarily attributed to its diverse functions in promoting tumour formation and conferring resistance to therapeutic interventions. This study presents an in silico drug repositioning approach that focuses on identifying specific inhibitors of STAT-3 for the purpose of treating breast cancer. We initially examined the structural and functional attributes of STAT-3, thereby elucidating its crucial involvement in cellular signalling cascades. A comprehensive virtual screening was performed on a diverse collection of drugs that have been approved by the FDA from zinc15 database. Various computational techniques, including molecular docking, cross docking, and cDFT analysis, were utilised in order to prioritise potential candidates. This prioritisation was based on their predicted binding energies and outer molecular orbital reactivity. The findings of our study have unveiled a Dihydroergotamine and Paritaprevir that have been approved by the FDA and exhibit considerable promise as selective inhibitors of STAT-3. In conclusion, the utilisation of our in silico drug repositioning approach presents a prompt and economically efficient method for the identification of potential compounds that warrant subsequent experimental validation as selective STAT-3 inhibitors in the context of breast cancer. The present study highlights the considerable potential of employing computational strategies to expedite the drug discovery process. Moreover, it provides valuable insights into novel avenues for targeted therapeutic interventions in the context of breast cancer treatment.

유전자를 중간 매개로 고려한 동시발생 기반의 약물-질병 관계 추론 (Co-occurrence Based Drug-disease Relationship Inference with Genes as Mediators)

  • 신상원;신예은;장기업;윤영미
    • 한국정보기술학회논문지
    • /
    • 제16권11호
    • /
    • pp.1-9
    • /
    • 2018
  • 신약 재창출은 현재 사용되는 약물의 새로운 용도를 발견하는 방법이다. 텍스트 마이닝은 정형화되지 않은 문서로부터 의미 있는 지식을 획득하는 과정을 의미한다. 본 논문에서는 약물-유전자와 유전자-질병에서 동시에 측정된 유전자 출현 빈도의 비율을 고려하여 새로운 약물-질병 관계를 추론하는 방법을 제안한다. 생물학적 문헌으로부터 약물-유전자와 유전자-질병의 동시출현 빈도를 측정하고 각 약물과 질병에 대하여 유전자의 출현 비율을 계산한다. 약물-질병 관계의 가중치는 동시에 측정된 유전자 출현 비율의 평균을 이용하여 계산되고 이를 이용하여 각 질병의 분류 정확도를 측정한다. 약물-질병 관계를 추론하는 것에서 동시출현 빈도를 문장 단위로 측정하고 여러 관계를 고려하는 방법이 기존 방법보다 더 정확히 식별해내는 것을 보였다.

NGSEA: Network-Based Gene Set Enrichment Analysis for Interpreting Gene Expression Phenotypes with Functional Gene Sets

  • Han, Heonjong;Lee, Sangyoung;Lee, Insuk
    • Molecules and Cells
    • /
    • 제42권8호
    • /
    • pp.579-588
    • /
    • 2019
  • Gene set enrichment analysis (GSEA) is a popular tool to identify underlying biological processes in clinical samples using their gene expression phenotypes. GSEA measures the enrichment of annotated gene sets that represent biological processes for differentially expressed genes (DEGs) in clinical samples. GSEA may be suboptimal for functional gene sets; however, because DEGs from the expression dataset may not be functional genes per se but dysregulated genes perturbed by bona fide functional genes. To overcome this shortcoming, we developed network-based GSEA (NGSEA), which measures the enrichment score of functional gene sets using the expression difference of not only individual genes but also their neighbors in the functional network. We found that NGSEA outperformed GSEA in identifying pathway gene sets for matched gene expression phenotypes. We also observed that NGSEA substantially improved the ability to retrieve known anti-cancer drugs from patient-derived gene expression data using drug-target gene sets compared with another method, Connectivity Map. We also repurposed FDA-approved drugs using NGSEA and experimentally validated budesonide as a chemical with anti-cancer effects for colorectal cancer. We, therefore, expect that NGSEA will facilitate both pathway interpretation of gene expression phenotypes and anti-cancer drug repositioning. NGSEA is freely available at www.inetbio.org/ngsea.

New conceptual approaches toward dentin regeneration using the drug repositioning strategy with Wnt signaling pathways

  • Lee, Eui-Seon;Kim, Tae-Young;Aryal, Yam Prasad;Kim, Kihyun;Byun, Seongsoo;Song, Dongju;Shin, Yejin;Lee, Dany;Lee, Jooheon;Jung, Gilyoung;Chi, Seunghoon;Choi, Yoolim;Lee, Youngkyun;An, Chang-Hyeon;Kim, Jae-Young
    • International Journal of Oral Biology
    • /
    • 제46권2호
    • /
    • pp.67-73
    • /
    • 2021
  • This study summarizes the recent cutting-edge approaches for dentin regeneration that still do not offer adequate solutions. Tertiary dentin is formed when odontoblasts are directly affected by various stimuli. Recent preclinical studies have reported that stimulation of the Wnt/β-catenin signaling pathway could facilitate the formation of reparative dentin and thereby aid in the structural and functional development of the tertiary dentin. A range of signaling pathways, including the Wnt/β-catenin pathway, is activated when dental tissues are damaged and the pulp is exposed. The application of small molecules for dentin regeneration has been suggested as a drug repositioning approach. This study reviews the role of Wnt signaling in tooth formation, particularly dentin formation and dentin regeneration. In addition, the application of the drug repositioning strategy to facilitate the development of new drugs for dentin regeneration has been discussed in this study.

A Potential Target of Tanshinone IIA for Acute Promyelocytic Leukemia Revealed by Inverse Docking and Drug Repurposing

  • Chen, Shao-Jun
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권10호
    • /
    • pp.4301-4305
    • /
    • 2014
  • Tanshinone IIA is a pharmacologically active ingredient extracted from Danshen, a Chinese traditional medicine. Its molecular mechanisms are still unclear. The present study utilized computational approaches to uncover the potential targets of this compound. In this research, PharmMapper server was used as the inverse docking tool andnd the results were verified by Autodock vina in PyRx 0.8, and by DRAR-CPI, a server for drug repositioning via the chemical-protein interactome. Results showed that the retinoic acid receptor alpha ($RAR{\alpha}$), a target protein in acute promyelocytic leukemia (APL), was in the top rank, with a pharmacophore model matching well the molecular features of Tanshinone IIA. Moreover, molecular docking and drug repurposing results showed that the complex was also matched in terms of structure and chemical-protein interactions. These results indicated that $RAR{\alpha}$ may be a potential target of Tanshinone IIA for APL. The study can provide useful information for further biological and biochemical research on natural compounds.

Identifying literature-based significant genes and discovering novel drug indications on PPI network

  • Park, Minseok;Jang, Giup;Lee, Taekeon;Yoon, Youngmi
    • 한국컴퓨터정보학회논문지
    • /
    • 제22권3호
    • /
    • pp.131-138
    • /
    • 2017
  • New drug development is time-consuming and costly. Hence, it is necessary to repurpose old drugs for finding new indication. We suggest the way that repurposing old drug using massive literature data and biological network. We supposed a disease-drug relationship can be available if signal pathways of the relationship include significant genes identified in literature data. This research is composed of three steps-identifying significant gene using co-occurrence in literature; analyzing the shortest path on biological network; and scoring a relationship with comparison between the significant genes and the shortest paths. Based on literatures, we identify significant genes based on the co-occurrence frequency between a gene and disease. With the network that include weight as possibility of interaction between genes, we use shortest paths on the network as signal pathways. We perform comparing genes that identified as significant gene and included on signal pathways, calculating the scores and then identifying the candidate drugs. With this processes, we show the drugs having new possibility of drug repurposing and the use of our method as the new method of drug repurposing.